Alternating Electric Field Therapy With IGF1R Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells develop resistance to alternating electric fields, reducing the efficacy of Tumor Treating Fields (TTFields) therapy, necessitating a combination therapy to enhance sensitivity and treatment outcomes.
Innovation Solution
Combining alternating electric fields with inhibitors of IGF1R, JNK, RPS6, or ERK to increase cancer cell sensitivity by exposing cells to these fields and administering therapeutically effective amounts of inhibitors such as antibodies, small molecules, or oligonucleotides to modulate protein expression and enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alternating electric fields (TTFields) are used to treat cancer cells, then cancer cell growth is inhibited, but cancer cells develop resistance reducing treatment efficacy
Solution Approach 1:
The patent combines TTFields with small interfering RNAs (siRNAs) that specifically target and reduce the expression of resistance-related genes (MDR1, BCL2, Survivin) in cancer cells. This dual approach merges physical field therapy with genetic intervention to prevent resistance development and maintain long-term treatment efficacy
Solution Approach 2:
The patent modifies the biological parameters of cancer cells by introducing siRNAs that change the expression levels of key proteins involved in drug resistance and apoptosis suppression. This parameter change at the molecular level enhances the cells' sensitivity to alternating electric fields over time
2Reliability
If inhibitors (IGFR1, JNK, RPS6, or ERK) are combined with alternating electric fields, then cancer cell sensitivity is increased, but treatment complexity increases
Solution Approach 1:
The patent uses specific molecular pathways (IGFR1, JNK, RPS6, ERK) as intermediaries to mediate the effect of alternating electric fields on cancer cells. By targeting these specific signaling pathways with inhibitors, the treatment enhances sensitivity through well-defined biological mechanisms rather than empirical combinations
Solution Approach 2:
The patent modifies key signaling pathway parameters (IGFR1 phosphorylation, JNK activity, RPS6 phosphorylation, ERK activity) to alter cancer cell response to alternating electric fields. These targeted parameter changes in specific molecular pathways provide a rational basis for combination therapy
Data Source
AI summary
Disclosed herein are methods of increasing sensitivity of a cancer cell to alternating electric fields comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength, and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor. Disclosed are methods of increasing treatment efficacy comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and/or ERK inhibitor to the subject. Disclosed are methods of treating a subject having cancer comprising applying an alternating electric field to a target site of the subject for a period of time, the alternating electric field having a frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more of an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and/or ERK inhibitor to the subject. Disclosed are methods of reducing viability of cancer cells using an alternating electric field for a period of time, the alternating electric field having a frequency and field strength in combination with either an IGF1R inhibitor, JNK inhibitor, RPS6 inhibitor, and/or ERK inhibitor. Disclosed are methods of increasing apoptosis of a cancer cell comprising exposing the cancer cell to an alternating electric field for a period of time, the alternating electric field having a frequency and field strength; and exposing the cancer cell to an IGFR1 inhibitor, JNK inhibitor, RPS6 inhibitor or ERK inhibitor.